BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Coronavirus (COVID-19) » Page 3

ReeLabs Approved to Conduct First and Only Stem Cell Trial Against COVID-19 in India

October 11, 2020 By Cade Hildreth (CEO) Leave a Comment

Stem cells covid-19 India

ReeLabs received permission from the Central Licensing Authority to conduct the first and only  trial in India using MSCs from placenta and umbilical cord tissue against COVID-19.

There are numerous publications that have documented the role of stem cell against COVID-19. Currently there are 23 stem cell trials in progress in US, UK, Japan, Germany, China, Spain, France and various other developed countries and hitherto published literature is extremely encouraging.

India is now all set to join this elite list. [Read more…]

Filed Under: Cord Blood, Coronavirus (COVID-19)

Cord Blood Registry (CBR®) by Generate Life Sciences Partners with NantKwest to Develop Covid-19 Treatment

October 8, 2020 By Cade Hildreth (CEO) Leave a Comment

CBR NantKwest COVID

CBR to Provide Umbilical Cord-Derived Cellular Material to NantKwest for additional COVID-19 Clinical Trials Utilizing MSC Therapy

Los Angeles, Calif., and El Segundo, Calif., August 10, 2020 – CBR® by Generate Life Sciences, the world’s largest private newborn stem cell bank, and NantKwest (Nasdaq: NK), a clinical-stage, natural killer cell-based immunotherapy company, announced a collaboration to develop a COVID-19 treatment leveraging newborn stem cells. CBR will provide research-donated umbilical cord tissue-derived mesenchymal stem cells (MSCs) to NantKwest for efficient and robust expansion utilizing their proprietary modular, closed bioreactor system from NantKwest affiliate ImmunityBio, Inc. [Read more…]

Filed Under: Cord Blood, Coronavirus (COVID-19), Press Releases, Stem Cell News Tagged With: cord blood, cord tissue

FDA Grants Organicell Expanded Access to Treat COVID-19 Patients with Zofin(TM)

September 29, 2020 By Cade Hildreth (CEO) Leave a Comment

organicell-covid-19-zofin

Miami, FL (September 29, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted expanded access for an intermediate size population allowing its proprietary therapeutic, Zofin for the treatment of COVID-19. [Read more…]

Filed Under: Coronavirus (COVID-19), Press Releases Tagged With: COVID-19

Three New COVID-19 Patients Treated with Zofin(TM) Report Improvement

September 2, 2020 By Cade Hildreth (CEO) Leave a Comment

Organicell COVID-19 clinical trial

Organicell Commences Phase I/II Clinical Trial Enrollment

Miami, FL (September 2, 2020) — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted emergency, expanded access approval to treat two mild to moderate COVID-19 patients and one “Long Hauler” post COVID-19 patient. [Read more…]

Filed Under: Coronavirus (COVID-19), Exosomes, Press Releases

Organicell Phase I/II Clinical Trial Update

August 18, 2020 By Cade Hildreth (CEO) Leave a Comment

Organicell Zofin

Lead Therapeutic Candidate To Be Named Zofin(TM)

Miami, FL (August 18, 2020) — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has partnered with Alternative Research Associates, LLC and Larkin Hospital in Miami, FL to initiate a randomized, double-blinded, placebo-controlled phase I/II clinical trial against COVID-19 of its lead therapeutic candidate, which has been rebranded as Zofin. [Read more…]

Filed Under: Coronavirus (COVID-19), Press Releases, Stem Cell News Tagged With: COVID-19

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 12
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Cell Therapy Manufacturing Survey - Selection Criteria for Choosing a CMO Partner
    Rated 0 out of 5
    $197 $97
  • Stem Cell Fact Sheet - Types of Stem Cells and their Use in Medicine
    Rated 0 out of 5
    $10
  • Global Database of Research Supply Companies Global Database of Research Supply Companies 2021
    Rated 0 out of 5
    $39

Featured Posts

Vitro Biopharma

Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

MSC market

How the MSC Market is Coming of Age in 2021

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.